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Treatment of primary tumors in patients is often followed by a prolonged clinical 
remission which terminates with the occurrence of a tumor morphologically identical 
to the primary. Such secondary tumors could have been formed by proliferation of 
tumor cells  transformed near the end of remission by the same oncogenic agent that 
induced  the  primary  tumor or by outgrowth of residual  primary tumor cells  that 
remained dormant throughout the clinical remission (1, 2). The tumor dormant state, 
can be defined as "a state in which tumor cells persist in a host for prolonged periods 
of time with little  net  growth" and which is terminated by an event which permits 
their rapid outgrowth. 
Hadfield (3)  first  drew attention to the concept of the dormant cancer cell in  1954 
when he noted the extremely long time interval between the excision of many human 
tumors and the occurrence of histologically identical tumors thereafter.  His observa- 
tion that these late-arising tumors, once clinically evident, had growth rates compa- 
rable to the primary tumor, indicates that until the event permitting tumor emergence 
occurred, tumor outgrowth was under restraint. The appearance of tumors, morpho- 
logically identical to but at sites distant from the primary tumor, years after apparent 
successful treatment  of the primary, suggests that  residual  metastases  persisted  in  a 
dormant  state  at  these  sites  throughout the  clinical  remission  (4). In addition,  the 
finding in unselected autopsies of an incidence of carcinoma in situ that is far greater 
than the incidence of overt tumors of the same kind in the population  (2),  suggests 
that a  tumor dormant state may sometimes precede primary tumor outgrowth. 
In spite of the probable frequent occurrence of clinical tumor dormancy, only a few 
animal  models have been  developed for studying the tumor dormant state.  Experi- 
mental tumor dormant states have been achieved by implantation of tumor cells into 
an avascular site (5), by deprivation of hormones on which tumor growth is dependent 
(6), and by excision of a primary tumor after metastasis has occurred (7). Oncogenic 
viruses have also been suppressed to a dormant state by using immunostimulants (8). 
The dormant state has been broken by vascularization of a formerly avascular tumor 
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site  (5), administration of hormones  (6), immunosuppression  (7), and surgical stress 
(9). 
We have previously reported (10) the occurrence of a tumor dormant state in DBA/ 
2 mice after their immunization and subsequent challenge with syngeneic lymphoma 
cells L5178Y.  These mice remained clinically normal for as long as 320 d  before the 
onset  of rapid tumor cell outgrowth.  Tumor  cells were  isolated from  the peritoneal 
cell  (PC) 1 population  of these  mice during  the period of clinical normalcy.  In  this 
paper,  we  report  on  the  early  events  involved  in  the  establishment  of the  tumor 
dormant state and relate these events to the subsequent prolonged clinical remission 
and eventual termination of tumor dormancy. 
Materials  and  Methods 
Mice.  DBA/2 female mice (8 wk of age) were obtained from The Jackson Laboratory, Bar 
Harbor, Maine 
Tumor Cell Lines.  DBA/2-derived methylcholanthrene-induced L5178Y lymphoma cells and 
benzanthraeene-induced EL-4 lymphoma cells derived from a C57BL/6 mouse were obtained 
from Dr. Lionel Manson of the Wistar Institute, Philadelphia, Pa. The L5178Y lymphoma is 
an immunogenic, weakly metastatic cell line in which as few as 10 cells injected i.p. into normal 
DBA/2 mice routinely produce ascitic tumors and death in nearly 100% of mice (11).  Friend 
leukemia virus-transformed DBA/2 erythroblasts designated clone 745 (GM86) were obtained 
from the Genetic Mutant Cell Repository, Camden, N.J. Both lymphoma lines were maintained 
by weekly i.p.  passage of 107 cells into normal syngeneic mice.  Additionally, all lines were 
maintained in vitro as suspension euhures  in RPMI-1640  growth medium  (pH  7.0)  (Grand 
Island Biological Co., Grand Island, N. Y.) supplemented with  15%  fetal calf serum,  2 mM 
glutamine, 100 U/ml of penicillin, and 100/tg/ml of streptomycin. All cultures were incubated 
at 37°C in a humidified chamber containing a 5% CO2 atmosphere. 
Immunization  of Tumor Recipients and Establishment  of the Dormant State.  L5178Y lymphoma cells 
(1  ×  106 cells per mouse)  were implanted subcutaneously on the ventral surface of DBA/2 
mice.  10 d later the resultant  1 cm diameter nodules were surgically excised, and 7 d later all 
mice were challenged intraperitoneally with 5  ×  104 L5178Y cells. Control mice which were 
immunized but not challenged were free of isolatable tumor cells and lived a normal lifespan. 
Clinical  Normalcy.  Immunized and challenged mice were judged to be clinically normal if: 
(a) the total body weight did not exceed 30 g, (b) the abdomen did not appear distended, (c) no 
macroscopic tumor loci were present in the peritoneal cavity, and  (d) the total peritoneal cell 
count  did not exceed  10 v cells. Tumor dormant mice were considered to have passed into a 
tumor emergent phase when their total PC count exceeded 10  7 cells. 
Antisera.  Alloantiserum was prepared in C57BL/6 mice by a series of 6 i.p. injections of 10  v 
L5178Y cells at 10-d intervals. 2 wk after the last injection all mice were exsanguinated and the 
serum fraction prepared. This serum contained high titers of cytolytic antibody active against 
normal and transformed DBA/2 cells, but not against cells of C57BL/6 origin. AKR anti-C3H 
thymocyte serum  (anti-Thy  1.2) was  purchased  from  Litton  Bionetics  (Kensington,  Md.). 
Nonconjugated as well as fluoreseein isothiocyanate (FITC)-conjugated rabbit anti-mouse IgG 
sera were obtained from Cappel Laboratories, Inc. (Cochranville, Pa.). 
Enumeration of Tumor Cells.  Single cell suspensions of various cell populations were prepared 
in supplemented RPMI-1640 at a concentration of l0  T cells/ml. 150/~1 of each suspension was 
added into the first well of each row of flat-bottomed mierotiter plates. A  series of threefold 
dilutions was then made into the remaining wells in each row. The plates were incubated for 
10-14  d  at  37°C  in  a  5%  CO2  humidified atmosphere  and  examined  daily for tumor cell 
outgrowth.  The  highest  dilution of each  suspension  which  yielded positive in  vitro  tumor 
outgrowth after incubation for  10-14 d  was identified, and the number of tumor cells in the 
l Abbreviations used in this paper: AR, absorbance  ratio; C', complement;  CMC, cell-mediated cytolysis; 
DPC, days post challenge; FCS, fetal calf serum; FITC, fluorescein isothiocyanate;  PC, peritoneal  cell; 
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original  suspension  was  calculated.  Culture  wells were scored  positive  for tumor  outgrowth 
when microscopic observation showed increasing numbers of large lymphoblastoid cells which 
continued to proliferate after transfer into new culture wells. Cells from such positive wells were 
invariably tumorigenic when implanted into normal DBA/2 mice. 
Cell Preparation 
EFVECTOR CELLS.  Mice were killed by cervical dislocation. Spleen cell and inguinal lymph 
node suspensions were prepared in supplemented RPMI-1640 by gentle flushing and aspiration 
through an  18-gauge needle. Debris was removed by passage through a nylon mesh screen. PC 
were  harvested  by  vigorous  lavage with  phosphate-buffered  saline  (PBS).  Peripheral  blood 
leukocyte suspensions were prepared from whole heparinized blood by centrifugation through 
Ficoll-Hypaque according to the procedure of BOyum  (12).  After washing,  the test cells were 
resuspended  to the appropriate concentration in supplemented  RPMI-1640. 
ADHERENT  AND  NONADHERENT EFFECTOR CELLS.  Peritoneal  cells  prepared  as  above  were 
diluted to a concentration of 10  7 cells/ml in supplemented RPMI- 1640.0.1 ml of this suspension 
was  placed  into  replicate  6-mm  flat-bottomed  microtiter  plate  wells,  and  suspensions  were 
incubated  at 37°C in a  humidified CO2 atmosphere for 2 h. The nonadherent  cells were then 
removed by gentle washing with 3 vol of supplemented  RPMI-1640.  These cells were washed 
three times in  1640,  resuspended  to 0.1-ml vol, and transferred  to fresh microtiter plate wells. 
The initial wells containing adherent cells received 0.1  ml of RPMI- 1640. These subpopulations 
served as effector cells in  18-h 51Cr-release assays as described below. 
ENRICHED  T  AND  B  SUBPOPULATIONS  OF  EFFECTOR  CELLS.  Peritoneal effector cells were assayed 
for sensitivity to treatment with either anti-Thy  1.2  +  C' or anti-Ig +  C'. Briefly, 4  ×  106 PC 
in 0.4 ml of supplemented  RPMI-1640 were incubated with either mouse anti-Thy  1.2 serum 
(Litton Bionetics)  +  C' or rabbit  anti-mouse Ig (Cappel  Laboratories)  +  C' at  37°C for  1 h 
with occasional agitation.  The anti-Thy  1.2  and  anti-Ig sera were used at  a  final dilution of 
1:10. Fresh frozen guinea pig serum served as the C' source and was used at a  final dilution of 
1 : 10. Controls included sera alone and C' alone. After treatment, cells were washed three times 
in media and  diluted  to the original volume. Treated  cell suspensions  were assayed  for their 
cytolytic activity against 51Cr-labeled L5178Y cells in the cell-mediated cytotysis (CMC) assay 
described below. 
TUMOR CELL TAROETS.  Tumor cells obtained from tissue culture or the peritoneal cavity of 
tumor-bearing mice were resuspended  in  1 ml of supplemented RPMI-1640 at a concentration 
of 5  ×  10  ~ cells/ml and incubated at 37°C for 90 min with  150/~Ci of Na251CrO4  (sp act 200- 
500 mCi/mg, New England  Nuclear,  Boston, Mass.).  After incubation,  the labeled cells were 
washed four times and resuspended  in supplemented  RPMI-1640. 
CMc ASSAY.  A  modification of the procedure described by Thorn et al.  (13)  was used  for 
CMC assays.  Briefly, 0.1  ml of effector cells (107/ml) was added  in triplicate or quadruplicate 
into the wells of a  flat-bottomed microtiter plate  (Costar,  Cambridge,  Mass.)  followed by the 
addition of 0.1  ml of target cells (105/ml)  giving an effector:target ratio of 100:1. 
The  plates  were  incubated  for  18  h  at  37~C  in  a  5%  CO2  humidified  atmosphere.  After 
incubation,  a  0.1-ml aliquot was removed from each well and counted  in a  well-type gamma 
•  .  51  counter (model  1185,  Nuclear Chicago, Des Plames, Ill.). Spontaneous release of  Cr, ranging 
from  16  to  28%,  was  determined  by  incubating  the  target  cells in  medium  alone  for  18  h. 
Maximum release of 51Cr was determined by hypotonic lysis of tumor targets and ranged from 
78 to 93%. The percentage of cytolysis was determined according to the formula: 
cpm released in test sample -  cpm of spontaneous release 
Percent cytolysis  =  ×  100. 
total releasable cpm -  cpm of spontaneous  release 
Antibody-Dependent Complement-Mediated Cytolysis Assay.  Serial twofold dilutions of heat-inac- 
tivated serum from tumor cell immunized and challenged mice were prepared in supplemented 
RPMI- 1640.  50/~1 vol of each serum dilution were plated in triplicate or quadruplicate into the 
wells of a  round-bottomed  microtiter plate  (Falcon Labware, Oxnard, Calif.) followed by the 
addition of 0.05 ml ofa 1:6 dilution of fresh-frozen guinea pig serum as a source of complement. 
Finally, 0.1  ml of labeled target cells (2  ×  105 cells/ml) was added to each well. 
The plates were sealed with adhesive plastic tape, shaken vigorously for 30 s, and incubated 
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centrifuged at 200 g for  10 min. A 0.1-ml aliquot was removed from each well and counted in 
a well-type gamma counter. Spontaneous release was determined by incubation of target cells 
in medium alone. Additionally, cytolysis by serum or complement was determined by incuba- 
tion of target cells in the presence of either serum alone or complement alone. Spontaneous 
release,  as  well  as  serum or  complement release,  ranged  from  3  to  7%.  The percentage of 
cytolysis was determined as described above. 
Indirect Radioimmunoassay.  The presence of cytophilic serum antibody was determined by a 
modification of a  radioimmunoassay procedure described by Sparks et  al.  (14). Briefly,  106 
L5178Y cells in 0.1 ml were added to 0.1 ml of serially diluted heat-inactivated serum obtained 
from tumor cell immunized and challenged mice. The mixture was incubated at R.T. for 60 
min with constant agitation. After incubation, the cells were washed eight times with PBS 
containing 10% FCS (PBS-FCS). To the cell pellet was added 35/~1 of a  1:100 dilution of 125I- 
labeled goat anti-mouse immunoglobulin.  The mixture was incubated at 5~C for 60 min with 
constant shaking. Afterward, the cells were washed nine times in PBS-FCS and the cell pellet 
counted in a well-type counter. The amount of specific binding is expressed  as an absorbance 
ratio (AR) which is determined by: 
AR =  cpm bound with experimental serum  ×  100. 
cpm bound with normal mouse serum 
Indirect Immunofluorescence Assay.  L5178Y cells were resuspended in PBS-FCS at a concentra- 
tion of 5  ×  106 cells/ml. 0.1 ml of cells was incubated with 0.1 ml of various dilutions of sera 
obtained from L5178Y cell immunized and challenged mice for 30 rain at 5°C. The cells were 
washed three times with PBS and the pellet resuspended to 0.1 ml. 0.1 ml of a  1:5 dilution of 
FITC-labeled goat anti-mouse serum was added and the mixture reincubated at 5°C for 30 
min. After further washing with PBS, cells were placed on clean glass microscope slides and 
sealed with glass cover slips. Slides were examined at  X 930 magnification  with an AO vertical 
illumination microscope with an HB-50 ultraviolet light source. 
Results 
I.  Enumeration  of L5178Y  Cells  in  the  Peritoneal  Cavity.  Because  the  events  to  be 
quantitated during the  establishment of the  L5178Y  cell  dormant state  are  to  be 
placed within the framework of cumulative mortality of the tumor dormant mice, we 
present  in Fig.  1 A  the  kinetics of tumor associated deaths  in normal and L5178Y 
immunized DBA/2 mice inoculated with 50,000 L5178Y cells i.p. A  similar cumula- 
tive mortality curve has been published previously (10). 
In our analysis of the establishment of L5178Y cell dormancy, we first measured 
the  number of tumor cells in the peritoneal cavity of L5178Y  cell immunized and 
challenged mice.  Immunized but  nonchallenged mice  lived a  normal lifespan, re- 
maining free of tumor cells in their peritoneal and spleen cell populations. Suspensions 
of  PC  were  prepared  from  immunized mice  on  various  days  with  respect  to  i.p. 
L5178Y cell challenge and serial threefold dilutions of these suspensions were cultured 
in wells of microtiter plates at 37°C and observed for outgrowth of tumor cells. The 
calculation of the  number of  tumor  cells  in  the  inoculum by  end-point dilution 
analysis was based on observations in our laboratory that one to three tumor cells are 
capable of outgrowth in culture wells during a  14-d incubation period  (our unpub- 
lished data). 
Fig.  1 B  illustrates that after i.p. challenge, the number of L5178Y cells increased 
and reached a  peak in 4 d, steadily declining thereafter to lower levels ranging from 
300 to  1,000 per mouse for the remainder of the tumor dormant state.  Beginning at 
48  d  postehallenge  (DPC),  some  mice  developed  ascitic  tumors  and  these  mice 
contained 107-108 tumor cells in the peritoneal cavity; the remaining  clinically  normal 736  TUMOR  DORMANCY:  TUMOR  CELL  NUMBERS  AND  IMMUNE  RESPONSE 
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Fla.  1A.  Tumor associated deaths in normal and L5178Y cell immunized mice after i.p. inocula- 
tion  of 5  ×  104 L5178Y  lymphoma cells. The nonimmunized control  group  (shaded histogram) 
contained 10 normal DBA/2 mice. The experimental group (open histogram) contained 30 L5178Y 
cell immunized age-matched mice. Groups of mice which were immunized but not challenged had 
no incidence of tumor-associated death  (not shown). Fzc.  1 B.  Numbers of L5178Y cells isolated 
from  the  peritoneal  cavity  of L5178Y  cell  immunized mice  before  and  after  i.p.  L5178Y  cell 
challenge  as  measured by  end  point  dilution  analysis.  Each  datum  point  represents the  mean 
number of tumor cells isolated from 6  to  12 individual mice. Mice were categorized as clinically 
normal or  tumor emergent on  the  basis of their  total  PC  numbers. For  each  datum point,  the 
standard  error  was  less  than  12%  of the  mean  value.  FxG. 1C.  Kinetics of tumor-specific eel[- 
mediated cytotoxicity in L5178Y cell immunized and challenged mice. Each datum point represents 
the 18-h CMC activity of peritoneal cells (solid line) or spleen cells (dashed line) present in a  pool 
of respective cell suspensions from three clinically normal mice/time point. The effector:target ratio 
in all cases was  100:1.  The standard error for each point is less than  10% of the mean value. The 
data expressed in Fig.  1 B and  1C are derived from several experiments, the values of which all fell 
within the indicated standard errors of the mean. 
mice  continued  to  harbor  300-1,000  tumor  cells  until  they  developed  emergent 
tumors. 
II.  Effect  of Cell Density on In  Vitro Isolation  of L5178Y Cells.  During  the  course  of 
tumor  cell  isolations  in  vitro,  an  observation  was  made  which  may  bear  on  the K. J.  WEINHOLD,  L.  T. GOLDSTEIN, AND E.  F.  WHEELOCK  737 
TAaLE  I 
Effect of Cell Density on Outgrowth of Tumor Cells In  Vitro  from Cultures of Peritoneal Cells Removed 
from Immunized Mice on Days after L5178Y Cell Challenge 
No. of peritoneal cells in 
each culture well 
Day of peritoneal cell collection after L5178Y cell challenge 
7  41  85 
No, of  Tumor  No. of tu-  Tumor  Tumor 
cell out-  mor cells  cell out-  tumor  cell out- 
cells  growth*  present  growth  growth  present 
No. of tu- 
mor cells 
present 
1.0 ×  106  0  6,561  0  81  +  243 
3.3 ×  105  0  2,187  +  27  +  81 
1.1  ×  105  0  729  +  9  +  27 
3.7 ×  104  0  243  +  3  +  9 
1.2 ×  104  0  81  +  1  +  3 
4.1  x  10  a  +  27  0  0  +  1 
1.4 X lO  a  +  9  0  0  0  0 
4.6 X 102  +  3  0  0  0  0 
1.5 X lO  s  +  1  0  0  0  0 
5.0 ×  10  ~  0  0  0  0  0  0 
Percent 61Cr release from 
10,000 L5178Y ceils in- 
cubated  with  106  peri- 
toneal cells~ 
86%  35%  3.2% 
* Determined by production of large numbers of lymphoblastoid cells in culture vessels during a  14-d 
incubation (see also Materials and Methods). 
PC cytolytic activity was determined in 18-h 51Cr release assays. 
suppressed state of L5178Y cells in vivo. Peritoneal cell populations collected from 
immunized mice on the  7th d  after L5178Y cell challenge contained approximately 
6,500 tumor cells per  106 peritoneal cells as calculated from the highest dilution well 
(containing 1.5  X  102 PC)  in which tumor cells grew out  (Table I). However, these 
results of tumor cell isolations were unexpected in that wells containing the highest 
concentrations of peritoneal cells in the same dilution series  (1.2  ×  104-1  ×  106), 
failed to yield tumor cell outgrowth after 14 d of incubation. Subculture of these wells 
at the end of the  14-d period also failed to yield tumor cell outgrowth, whereas tumor 
cells could be readily subcultured from wells in which outgrowth occurred. A similar 
observation was made with peritoneal cells collected 41 d after L5178Y cell challenge. 
In this dilution series, however, a total of 81  tumor cells were calculated to be present 
per  1  ×  106 peritoneal cells, but only the first well of the dilution series, containing 
1 ×  106 peritoneal cells, failed to yield tumor cell outgrowth. Finally, on day 81  after 
L5178Y  cell  challenge,  243  tumor cells were  calculated to  be present  in  1  ×  106 
peritoneal cells, but no inhibition of tumor cell outgrowth was observed in any of the 
wells containing high concentrations of cells. 
As seen in Table I, the degree of inhibition of L5178Y cell outgrowth in the high 
cell  density wells occurred  with  both  high  (86%)  and low  (35%)  L5178Y  cytolytic 
activity  by  peritoneal  cells  (see  section  IV),  but  did  not  occur  in  the  absence  of 
cytolytic activity. The level of cytolytic activity correlated with the number of wells 
in the early part  of the dilution series in which  no tumor cell outgrowth occurred. 
Inhibition of tumor cell outgrowth in wells containing high cell densities was not due 738  TUMOR  DORMANCY:  TUMOR  CELL NUMBERS  AND  IMMUNE  RESPONSE 
TABLE II 
Antibody to L5178Y Cells in Serum of L5178Y Cell Immunized and Challenged 
Mice 
Days after L5178Y cell chal- 
lenge 
Antibody to L5178Y cells 
Cytolytic*  Cytophilic~ 
%  % 
51Cr Re-  Fluorescent  AR-binding 
lease  cells 
0  2.1  <1  1.2 
10-14  3.3  <1  1.4 
28-35  2.9  <1  2.6§ 
45-50  2.5  2  1.3 
65-80  2.3  <1  ND 
Normal mouse serum  1.9  2  1.0 
C57BL/6 anti-DBA/2  99.3  95  10.5 
serum 
* Sera assayed for cytolytic activity were tested at a  1:20 final dilution  and C' was 
used at a  1:32 final dilution.  Target cells consisted of 51Cr-labeled tissue culture 
L5178Y targets. 
:~ Sera assayed for eytophilic activity were tested at a 1:10 final dilution using tissue 
culture L5178Y cells, 
§ A singular peak of antibody was detected in three individual experiments between 
days 28 and 35 with no antibody detected on other days. 
to cell population effects because wells containing identical numbers of normal DBA/ 
2  PC  failed to inhibit the outgrowth of a  comparable number of exogenously added 
L5178Y cells (data not shown). Additionally, cultures refed at 3-d intervals inhibited 
the  outgrowth  of tumor  cells to  the  same  degree  as cultures  which  were  not  refed 
(data not shown). The inhibition of L5178Y cell outgrowth in the early culture wells 
could not be due to higher ratios of effeetor to target cells since this ratio was constant 
throughout the titration. 
III.  Humoral  Immune Responses  to  L5178Y Cells.  To  determine  whether  mice  im- 
munized and challenged with  L5178Y  cells produce anti-tumor antibodies, we bled 
mice on selected days and assayed the serum fraction for:  (a) complement-dependent 
cytolytic antibody,  (b)  cytophilic antibody by indirect immunofluorescence,  and  (c) 
cytophilic  antibody  by  indirect  radioimmunoassay.  Table  II  shows  that  cytolytic 
antibody was not observed at any of the times tested throughout  the lifespan of the 
mice.  Cytophilic antibody was  not  detected by indirect  immunofluorescence  assay. 
However,  indirect  radioimmunoassay revealed a  small peak  of cytophilic antibody 
activity  at  31  DPC.  Attempts  to  demonstrate  antibody-dependent  cell-mediated 
cytolysis with these sera were negative (data not shown). 
IV.  Kinetics of Cell-Mediated Lysis of L5178 Y Cells.  The sharp decline in tumor cell 
numbers  in the peritoneal cavity on  the 5th  d  after i.p. L5178Y  cell challenge  (Fig. 
1 B) in the absence of a detectable humoral response, suggested that an active cellular 
immune  response  had  been  elicited  against  the  tumor.  To  test  this  we  assayed 
peritoneal  and  spleen  cell populations,  removed  from  immunized  mice on  selected 
days before and after i.p. L5178Y cell challenge, for in vitro cytolytic activity against 
SlCr-labeled L5178Y  target cells. 
As shown  in  Fig.  1 C,  cytolytic activity was  detected  in  both  the  peritoneal and K.  J.  WEINHOLD,  L.  T.  GOLDSTEIN,  AND  E.  F.  WHEELOCK 
TABLE  III 
Characterization of Cytolytic Effector Cells in L5178 Y Cell Immunized and Challenged Mice 
739 
Effector peritoneal cells 
Day of cell 
collection 
after 
L5178Y cell 
challenge 
Percent 51Cr release from target cells:~ 
Cell population*  L5178Y  FLC-745  EL-4 
Whole  99.3%  6.7%  5.5% 
Adherent  9.1  0.6  2.0. 
Nonadherent  96.4  5.1  2.6 
14  Whole  46.6%  4.3%  3.9% 
Adherent  5.5  0.6  0.2 
Nonadherent  46.3  2.1  4.0 
35  Whole  40.7%  3.9%  5.3% 
Adherent  6.3  1.1  1.5 
Nonadherent  39.5  3.6  4.8 
60  Whole  3.7%  2.5%  1.9% 
Adherent  0.6  1.0  0.3 
Nonadherent  3.3  2.8  1.3 
* Whole cell populations consisted of 106 PC. Triplicate samples of adherent and nonadherent 
subpopulations of PC were prepared as described in Materials and Methods section. During 
the  time intervals tested,  nonadherent  subpopulations represented 60-70%  of whole PC 
populations. 
104  SICr-labeled  tumor  cell  targets  were  added  to  all  wells  and  CMC  activity  was 
determined in  18-h assays. 
spleen cell populations within 7 d  after subcutaneous implantation of L5178Y cells. 
Excision  of the  tumor  nodules was  followed by  increased  peritoneal  cell  cytolytic 
activity which peaked 4  d  postsurgery and then declined to lower levels by day 7. 
Intraperitoneal challenge with L5178Y cells, 7 d after tumor nodule excision, stimu- 
lated cytolytic activity which reached maximum levels 4 d after challenge and then 
fell sharply during the next 10 d, declining gradually thereafter to undetectable levels 
by the 70th d postchallenge. Spleen cell cytolytic activity remained low to undetect- 
able  throughout  the  postchallenge  period  (Fig.  1 C).  Lymph node and  peripheral 
blood lymphocyte populations had no measurable cytolytic activity throughout the 
entire time period tested (data not shown). 
V.  Characterization  of the Peritoneal  Effector Cells.  The cytolytic activity of PC resided 
solely in the nonadherent cell population throughout the 60-d period after L5178Y 
cell challenge (Table III). This cytolytic activity was specific for L5178Y cells and did 
not cross-react with EL-4 and FLC-745 cells. 
As shown in Table IV the cytolytic activity of PC was abolished by treatment with 
anti-Thy 1.2  +  C', but not by anti-Ig +  C' treatment, indicating a T-cell lineage of 
the cytolytic effector cells. 
Discussion 
In  this  report  we  have  quantitated  L5178Y  cell  growth  and  host  anti-tumor 
responses  in  L5178Y  cell  immunized and  challenged syngeneic DBA/2  mice,  and 740  TUMOR  DORMANCY:  TUMOR CELL NUMBERS  AND IMMUNE RESPONSE 
TABLE IV 
Effect of Anti-Thy 1.2 and Anti-Ig Treatment upon PC Anti-Tumor 
Cell-Mediated Cytotoxicity 
Treatment*  Cytolytic activity 
after treatment  (_ SEM):~ 
% 
Medium  89.9 (+ 2.7) 
Complement  56.7 (+ 1.4) 
Anti-Thy 1.2  71.5 (±4.4) 
Anti-Thy 1.2 +  complement  1.7 (+0.1) 
Anti-Ig  86.3 (±0.4) 
Anti-Ig +  complement§  89.0 (± 2.3) 
* Cells were treated before assay as indicated in Materials and Methods. 
~: CMC against SlCr-L5178Y  cells was assayed in an 18-h assay with peritoneal 
cells removed from mice 5 d postchallenge at an effector:target ratio of 100: 
1 based on initial cell concentrations before treatment. 
§ Comparable treatment  of normal DBA/2 spleen cells with anti-Ig  +  com- 
plement reduced a subsequent lipopolysaccharide response by 94% but had 
no effect upon the Con A response (data not shown). 
related these to the establishment  and course of tumor dormancy. After i.p. challenge 
of immunized  mice,  the  L5178Y tumor cell  population  passes  through four phases: 
(a)  increase  in  cell  numbers,  (b)  reduction  in  cell  numbers,  (c)  dormancy,  and  (d) 
emergence. The initial  growth of tumor cells after i.p.  inoculation  is logarithmic for 
~4  d,  during  which  time  a  secondary  cell-mediated  cytolytic  anti-tumor  response 
against  L5178Y cells  is stimulated.  Tumor cell  numbers  and cytolytic activity both 
reach  maximum  levels at  about  the 4th  d  after challenge and  both  decline  rapidly 
thereafter.  The  numbers  of tumor  cells  fall  to  approximately  300-1,000  cells  per 
mouse by the 30th-d after challenge and remain  at this  level for the duration  of the 
dormant state. 
The  level  of cytolytic  activity  of peritoneal  cells  is  probably  greater  than  our 
measurements  would  indicate,  because  the  unlabeled  tumor  cells  present  in  the 
peritoneal  cell  population  could be expected  to compete with  51Cr-labeled  L5178Y 
target cells for lysis by T  cells  (15). The coexistence of peak tumor cell numbers and 
maximum  cytolytic activity 4  d  after  tumor cell challenge indicates  that  tumor cell 
growth proceeded while the secondary cytolytic response was being generated.  How- 
ever, after attainment  of peak cytolytic activity, almost all of the tumor cells  (>99%; 
Fig.  1 B) were eliminated over a 25-d period. The cells in the tumor population which 
survive  must  possess  certain  characteristics  for escape  from  immune  cytolysis.  The 
data to be reported in the accompanying paper (15) suggests that this escape involves 
decreased  expression  of cell  surface  tumor  antigen.  Such  decreased  tumor  antigen 
expression  could  result  from  antigenic  modulation  (16),  immune  selection  (17),  or 
antigen  masking  (18).  Also, expression  of surface  antigen  has been reported  to vary 
quantitatively  as a  cell passes through stages in the cell cycle (19-21).  Thus a  tumor 
cell  arrested  in  a  specific  stage  of the  cell  cycle could  display  insufficient  surface 
antigen for it to be lysed. 
Recently,  Gelfant  (22)  proposed  that  tumor  cells  can  be  subdivided  into  four 
distinct categories:  (a) cycling cells, (b) noncycling Ga-blocked cells, (c) noncycling G2- 
blocked cells, and (d) noncycling G0-blocked cells, and speculated that the major pool 
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ulation.  The  finding  that  continuous  exposure  of both  experimental  and  human 
tumor cells to tritiated thymidine fails to label all cells within the population supports 
the concept of noncycling cell pools (23-25).  In tumor dormancy, tumor cells may 
escape by remaining in a noncycling stage until host anti-tumor activity has declined. 
An  essential  component  in  tumor  dormancy is  control of tumor  cell outgrowth 
which may be host imposed or intrinsic to some members of the tumor population. 
This  restraint  can  be  manifested  as  arrest  of cell  division,  a  slowed  rate  of cell 
proliferation or a normal rate of proliferation offset by a commensurate degree of cell 
death. A variety of host mechanisms for restraint of proliferating tumor cells has been 
described (26-29). In our tumor dormant model CMC persisted at low levels through- 
out the early stages of the tumor dormant period. A comparison of tumor-associated 
deaths  and  PC  cytolytic activity  (Fig.  1 A  and  1 C)  reveals that  tumor emergence 
occurred most frequently after day 70, during the period when CMC was no longer 
demonstrable in  the remaining clinically normal  mice. Because CMC  activity was 
determined with peritoneal cells pooled only from clinically normal mice, we are not 
able  to  comment  on  the  immune  status  of the  mice  in  which  tumor  emergence 
occurred before day 70. However, the prolonged period of clinical normalcy after the 
disappearance of detectable CMC activity suggests that other host tumor suppressive 
mechanisms, possibly cytostatic in nature, may be operative in later maintenance of 
the tumor dormant state. 
The gradual decline in cell-mediated cytolytic activity described here could be the 
result of a  number of previously described immunologic phenomena. Among these 
are:  (a)  an  age-related  decline  in  immune  responsiveness,  (b)  absence of sufficient 
immunogenic  stimulation  needed  to  maintain  an  ongoing  response  (15,  30),  (c) 
immune  paralysis  due to constant  low level stimulation  over prolonged periods of 
time (31), (d)  the production and slow release by tumor cells of immune suppressive 
substances (32), and finally, (e) the generation of suppressor cells capable of inhibiting 
cell-mediated cytolysis (33). Inhibition of CMC by increasing numbers of potentially 
competitive cold tumor cell targets within the PC population is not a  likely consid- 
eration because only clinically normal  mice  (i.e.  total  PC  <  107) were assessed  for 
CMC  activity,  and  these  mice  consistently  harbored  <103  tumor  cells  in  their 
peritoneal cell population. 
The in  vitro suppression  of tumor cell outgrowth observed only in culture wells 
containing  the  highest  number  of peritoneal  effector cells  suggests  the  possible 
importance  of localized  effector cell  density  upon  the  outcome of host-tumor cell 
interactions in  tumor dormant  mice.  In vitro suppression of tumor outgrowth was 
evident only during the period when CMC activity was demonstrable and the degree 
of suppressive activity, as reflected by the density of peritoneal cells required to inhibit 
tumor cell outgrowth, declined during the period of decreasing CMC activity. Thus 
the in vitro inhibition of tumor cell outgrowth is seemingly related to CMC activity 
yet is cell density dependent. This may reflect increased effector cell viability, more 
efficient cell recruitment  for killing, or the production of greater concentrations of 
tumor suppressive factors in high cell density culture wells. 
A  number of reports describe the generation of tumor specific humoral  immune 
responses (34-36). In our experiments only a late transient peak of low level cytophilic 
antibody was detected after L5178Y cell immunization and challenge. Benjamini et 
al.  (37)  have  described  a  cell-mediated  tumor-specific  response,  exclusive  of any 
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EL-4 cells. Recently, Fridman et al. (32)  have described an immunoglobulin binding 
factor,  released  by L5178Y  cells,  which  suppresses  the  in  vitro plaque  response  of 
mouse spleen cells to sheep erythrocytes. Although the activity of this factor has only 
been  assayed  in  vitro,  it  is  possible  that  such  a  factor  may  be  responsible  for 
suppression of humoral anti-tumor responses in vivo without affecting the early cell- 
mediated immune responses. 
The events leading to the breakdown of tumor dormancy and subsequent emergence 
of tumor remain elusive. In our system tumor emergence appears to be related both 
to  a  decline  in  host  anti-tumor  CMC  activity  and  to  presence  of a  tumor  cell 
subpopulation  which  manifests  increased  resistance  to  CMC  (15).  In  the  tumor 
dormant  model of Fisher and  Fisher  (9), surgical trauma was sufficient stimulus  to 
provoke tumor emergence.  Various  substances,  including  hormones,  heavy metals, 
and  nucleotides  have  been  found  to  be  capable  of  tumor  cell  stimulation  (22). 
Treatments  causing  immunosuppression  such  as  anti-lymphocyte  serum  (38),  X- 
irradiation or thoracic duct drainage (7) have also been shown to stimulate growth of 
dormant tumor cells. 
The demonstration that immunized mice can suppress a tumor cell challenge to a 
dormant state suggests that tumor dormancy may be a common phenomenon which 
often goes unrecognized and is mistaken for tumor rejection, because experiments are 
usually terminated  before the suppressed cells can emerge to produce overt tumors. 
Tumor dormancy results from the establishment of a delicate balance between tumor 
cell and host. The identification of mechanisms by which tumor cells escape destruc- 
tion  by tumor suppressive responses and  yet are restrained  from outgrowth  should 
lead  to an understanding  of persistence of tumor cells in patients during prolonged 
clinical remission. 
Summary 
Subcutaneous  implantation  of  DBA/2-derived  L5178Y  cells  into  DBA/2  mice 
followed  10  d  later  by  nodule  excision  protected  100%  of  mice  from  the  rapid 
outgrowth  of an  intraperitoneal  challenge  of L5178Y  cells  given  7  d  postexcision. 
Challenged mice remained clinically normal for 48-250 d before onset of an ultimately 
fatal tumor outgrowth. The numbers of L5178Y cells in the peritoneal cavity increased 
logarithmically for 4 d after challenge and then declined to low but detectable levels 
which persisted throughout  the clinically normal period. Cells active in  18-h in vitro 
cytolytic assays against mCr-labeled L5178Y target cells were found in the peritoneal 
cavity. The effector cells were determined  to be Thyl.2 positive. Their activity was 
tumor specific and reached peak levels 4 d  after tumor challenge and then gradually 
declined to undectable levels during the following 70 d. Tumor emergence occurred 
most frequently during the period when CMC activity was no longer demonstrable in 
the  remaining clinically normal mice. A  transient  peak of low level cytophilic anti- 
tumor antibody was detected  about  30  d  after tumor cell challenge.  The temporal 
associations between the numbers of tumor cells and the levels of cell-mediated lysis 
against  L5178Y cells indicate the importance of the cell-mediated cytolysis response 
in limiting initial tumor outgrowth and suggest its role as one of the factors responsible 
for long-term tumor suppression during tumor dormancy. 
The authors gratefully acknowledge Mark Marsili  for his assistance  in the performance of the 
radioimmune assays,  and  Ms.  Wilhelmina Marum  and  Ms.  Saidee  Ling for their technical K. J.  WEINHOLD,  L. T. GOLDSTEIN, AND E.  F. WHEELOCK  743 
assistance. We thank Dr. Catherine E. Calkins and Dr. Preston A. Marx for their discussions 
and critical reading of the manuscript. We also thank Ms. Dottle Sehmidt and Ms. Rita Bell 
for typing the manuscript. 
Received  for publication 13 November 1978. 
References 
I.  Fialkow, P. J., E. Klein, G. Klein, P. Clifford, and S. Singh.  1973. Immunoglobulin and 
glucose-6-phosphate dehydrogenase as markers of cellular origin in Burkitt lymphoma. J. 
Exp.  Med.  138:89. 
2.  Wheelock, E. F., L. T. Goldstein, K. J. Weinhold, W. P. Carney, and P. A. Marx. 1977. In 
Cancer invasion and metastasis: biologic mechanisms and therapy. Raven Press, S. B. Day, 
editor. 
3.  Hadfield, G. 1954. The dormant cancer cell. Br. Med. J.  2:607. 
4.  DerHagopian, R. P., E. V. Sugarbaker, and A. Ketcham.  1978. Inflammatory oncotaxis. 
J.  Am. Med.  Assoc. 240:374. 
5.  Gimbrone,  M.  A., Jr.,  S.  B.  Leepman,  R.  S.  Cotran,  and  J.  Folkman.  1972. Tumor 
dormancy in vivo by prevention of neovascularization. J.  Exp. Med.  136:261. 
6.  Noble, R.  L., and L. Hoover.  1975. A  classification of transplantable tumors in Nb rats 
controlled by estrogen from dormancy to autonomy. Cancer Res. 35:2935. 
7.  Eccles, S. A., and P. Alexander. 1975. Immunologically-mediated  restraint of latent tumour 
metastases. Nature  (Lond.).  257:52. 
8.  Wheelock, E. F., N. L. Caroline, and R. D. Moore. 1969. Suppression of established Friend 
virus leukemia by statolon. I. Demonstration of a latent infection in clinically normal mice. 
J.  Virol. 4:1. 
9.  Fisher, B., and E. R. Fisher. 1959. Experimental evidence in support of the dormant tumor 
cell. Science (Wash. D.  C.).  130:918. 
10.  Weinhold,  K. J.,  L.  T.  Goldstein, and  E.  F.  Wheelock.  1977. Tumour-dormant  states 
established with  L5178Y  lymphoma cells in  immunized  syngeneic murine hosts.  Nature 
(Lond.).  270:59. 
11.  Parr, I. 1972. Response of syngeneic murine lymphomata to immunotherapy in relation to 
the antigenicity of the tumour. Br. J.  Cancer. 26:174. 
12.  B0yum, A. 1968. Separation of leucocytes from blood and bone marrow. Scand. J. Clin. Lab. 
Invest.  21:1. 
13.  Thorn,  R. M., J. C. Palmer, and L. A. Manson.  1974. A simplified SICr-release assay for 
killer cells.J. Immunol.  Methods.  3:301. 
14.  Sparks, F. C., C.  C.  Ting, W. G.  Hammond, and  R.  B.  Herberman.  1969. An isotopic 
antiglobulin technique for measuring antibodies to cell-surface antigens. J.  Immunol.  102: 
842. 
15.  Weinhold,  K. J.,  D.  A.  Miller, and  E.  F.  Wheelock.  1979. The  tumor  dormant  state. 
Comparison of L5178Y cells used to established dormancy with those that emerge after its 
termination.J. Exp. Med.  149:745. 
16.  Boyse, E. A., L. J. Old, and S. Luell. 1963. Antigenic properties of experimental leukemias. 
II. Immunological studies in vivo with C57BL/6 radiation-induced leukemias.J. Natl.  Cancer 
Inst.  31:987. 
17.  Fenyo, E. M., E. Klein, G. Klein, and K. Swiech.  1968. Selection of an immunoresistant 
Moloney lymphoma subline with decreased concentration of tumor-specific surface anti- 
gens. ft.  NatL  Cancer Inst.  40:69. 
18.  Sanford, B. H.  1967. An alteration in tumor histocompatibility induced by neuraminidase. 
Transplantation  (Baltimore.).  5:1273. 
19.  Cikes,  M.  S.,  and  S.  Friberg.  1971. Expression  of  H2  and  Moloney  leukemia  virus 744  TUMOR  DORMANCY:  TUMOR  CELL  NUMBERS  AND  IMMUNE  RESPONSE 
transformed cell surface antigens in synchronized cultures of a mouse cell line. Proc. Natl. 
Acad. Sci. U. S. A. 68:566. 
20.  Shipley, W. U.  1971. Immune cytolysis in relation to the growth cycle of Chinese hamster 
cells. Cancer Res. 31:925. 
21.  Lerner, R. A., M. B. A. Oldstone, and N. R. Cooper.  1971. Cell cycle-dependent immune 
lysis of Moloney virus-transformed lymphocytes: presence of viral antigen, accessibility to 
antibody, and complement activation. Proc. Natl.  Acad. Sci. U. S. A. 68:2584. 
22.  Gelfant, S.  1977. A new concept of tissue and tumor cell proliferation. Cancer Res. 37:3845. 
23.  Mendelsohn, M. L.  1962. Chronic infusion of tritiated thymidine into mice with tumors. 
Science (Wash. D. C.).  135:213. 
24.  Clarkson, B., K. Ota, T. Ohkita, and A. O'Conner. 1965. Kinetics of proliferation of cancer 
cells in neoplastic effusions in man. Cancer. 18:1189. 
25.  Clarkson, B., J. Fried, T. C. Chou, A. Strife, R. Ferguson, S. Sullivan, T. Kitahara, and A. 
Oyama.  1977. Duration  of  the  dormant  state  in  an  established  cell  line  of human 
hematopoietic cells. Cancer Res. 37:4506. 
26.  Krahenbuhl, J. L., L. H. Lambert, Jr., and J. S. Remington. 1976. The effects of activated 
macrophages on tumor target cells: escape from cytostasis. Cell. Immunol. 25:279. 
27.  North, R. J., and D. P. Kirstein. 1977. T-cell-mediated concomitant immunity to syngeneic 
tumors.J. Exp. Med.  145:275. 
28.  Reese, A. B., A. E. Arenas, and I. S. Jones.  1970. Necrosis of malignant melanoma of the 
choroid. Am. J.  Ophthalmol. 69:91. 
29.  Sindelar, W. F., and A. S. Ketcham.  1974. Regression of cancer following surgery. Natl. 
Cancer Inst.  Monogr. 44:81. 
30.  Lefford, M. J.,  and  D.  D.  McGregor.  1974. Immunological memory  in  tuberculosis. I. 
Influence of persisting viable organisms. Cell Irnmunol. 14:417. 
31.  Weigle, W. O.  1973. Immunological unresponsiveness. Adv. Immunol. 16:61. 
32.  Fridman, W.  H., A. Guimezanes, and  R.  H. Gisler.  1977. Characterization of immuno- 
globulin-binding factor (IBF). J. Immunol. 119:1266. 
33.  Dresser, D. W., and N. A. Mitchison.  1968. The mechanisms of immunological paralysis. 
Adv. Immunol. 8:129. 
34.  Ting, C. C., and R. B. Herberman.  1974. Serological analysis of the immune response to 
Friend virus-induced leukemia. Cancer Res. 34:1676. 
35.  Herberman, R. B., D. A. Campbell, Jr., R. K. Oldham, G. D. Bonnard, C. C. Ting, H. T. 
Holden, M. Glaser, J. Djeu, and R. Oehler. I976. Immunogenicity of tumor antigens. Ann. 
N.  E  Acad Sci. 276:26. 
36.  Harada, M., G. Pearson, L. Redmon, E. Winters, and S. Kasuga.  1975. Antibody produc- 
tion and interaction with lymphoid cells in relation to tumor immunity in the Moloney 
sarcoma virus system.J. Irnmunol. 114:1318. 
37.  Benjamini, E., S. Fong, C. Erickson, C. Y. Leung, D. Rennick, and R. J. Scibienski. 1977. 
Immunity to lymphoid tumors induced in syngeneic mice by immunization with mitomycin 
C-treated cells. J. Immunol.  118:685. 
38.  DeCosse,  J.  J.,  and  S.  Gelfant.  1968. Noncycling  tumor  cells:  mitogenic  response  to 
antilymphoeyte serum. Science (Wash.  D. C.).  162:698. 